Abstract:Tumor necrosis factor-α (TNF) is well known for its cytotoxic effect on malignant cells. Its role in cell cycle control is relatively less known. In this study, we found that TNF induced G1 arrest of TF-1 and MV4–11 cells while simultaneously causing apoptosis. Treatment of the cells with TNF for 48 h caused cell cycle arrest, accompanied by dephosphorylation of pRb and reduction in D-type cyclin expression. The down-regulation of the D-type cyclins resulted in ∼50–80% decrease of the cyclin-dependent kinase activities. Cells treated with calpain-dependent inhibitor ALLN and apoptosis inhibitor zVAD-FMK suppressed degradation of IκBα and activation of caspase 3, respectively. However, treatment of cells with these two inhibitors was not able to prevent TNF-induced down-regulation of the D-type cyclins. In contrast, proteasome inhibitor MG-132 and lactacystin blocked both TNF-induced degradation of IκBα and down-regulation of D-type cyclins. These data suggest that down-regulation of D-type cyclins by TNF may be proteasome-proteolysis dependent. Additional support for this conclusion was obtained from experiments showing an increase of proteasome activity in TNF-treated cells and in vitro degradation of cyclin D3 by 26 S proteasome. Tumor necrosis factor-α (TNF) is well known for its cytotoxic effect on malignant cells. Its role in cell cycle control is relatively less known. In this study, we found that TNF induced G1 arrest of TF-1 and MV4–11 cells while simultaneously causing apoptosis. Treatment of the cells with TNF for 48 h caused cell cycle arrest, accompanied by dephosphorylation of pRb and reduction in D-type cyclin expression. The down-regulation of the D-type cyclins resulted in ∼50–80% decrease of the cyclin-dependent kinase activities. Cells treated with calpain-dependent inhibitor ALLN and apoptosis inhibitor zVAD-FMK suppressed degradation of IκBα and activation of caspase 3, respectively. However, treatment of cells with these two inhibitors was not able to prevent TNF-induced down-regulation of the D-type cyclins. In contrast, proteasome inhibitor MG-132 and lactacystin blocked both TNF-induced degradation of IκBα and down-regulation of D-type cyclins. These data suggest that down-regulation of D-type cyclins by TNF may be proteasome-proteolysis dependent. Additional support for this conclusion was obtained from experiments showing an increase of proteasome activity in TNF-treated cells and in vitro degradation of cyclin D3 by 26 S proteasome. Tumor necrosis factor-α (TNF) 1The abbreviations used are: TNFtumor necrosis factor-αTGFβtransforming growth factor-βGM-CSFgranulocyte macrophage-colony stimulating factorRPAribonuclease protection assayGAPDHglyceraldehyde-3-phosphate dehydrogenase1The abbreviations used are: TNFtumor necrosis factor-αTGFβtransforming growth factor-βGM-CSFgranulocyte macrophage-colony stimulating factorRPAribonuclease protection assayGAPDHglyceraldehyde-3-phosphate dehydrogenase is a multifunctional cytokine affecting a wide range of biological activities of many cell types, including endothelial cells, fibroblasts, and hematopoietic cells (1.Gamble J.R. Harlan J.M. Klebamoff S.J. Vadas M.A. Proc. Natl. Acad. Sci. U. S. A. 1985; 82: 8667-8671Crossref PubMed Scopus (781) Google Scholar, 2.Sugarman B.J. Aggarwal B.B. Hass P.E. Figari I.S. Palladino M.A. Shepard H.M. Science. 1985; 230: 943-945Crossref PubMed Scopus (1360) Google Scholar, 3.Zucali J.R. Elfebein J. Barth K.C. Dinarello C.A. J. Clin. Invest. 1987; 80: 772-777Crossref PubMed Scopus (49) Google Scholar, 4.Jacobsen S.E.W. Ruscetti F.W. Dubois C.M. Keller J.R. J. Exp. Med. 1992; 175: 1759-1772Crossref PubMed Scopus (86) Google Scholar, 5.Rusten L.S. Smeland E.B. Jacobsen F.W. Lien E. Lesslauer W. Loetsche H. Dubois C.M. Jacobsen S.E.W. J. Clin. Invest. 1994; 94: 165-172Crossref PubMed Scopus (62) Google Scholar, 6.Zhang Y. Harada A. Bluethmann H. Wang J.B. Nakao S. Mukaida N. Matsushima K. Blood. 1995; 86: 2930-2937Crossref PubMed Google Scholar). Its unique killing effect on malignant cells has been well established (7.Carswell E.A. Old L.J. Kassel R.L. Green S. Fiore N. Williamson B. Proc. Natl. Acad. Sci. U. S. A. 1975; 72: 3666-3670Crossref PubMed Scopus (3729) Google Scholar), which is mediated by the mechanism of programmed cell death (apoptosis) and necrosis (8.Elias L. Moore P.B. Rose S.M. Biochem. Biophys. Res. Commun. 1988; 157: 963-969Crossref PubMed Scopus (27) Google Scholar). During early apoptosis, a family of cysteine proteases, the caspases, is activated. The pathway from TNF receptor to initial caspase activation is reasonably well characterized. Unlike apoptosis, necrosis is not an energy-requiring process and is a less ordered event resulting in cell swelling or shrinkage and disruption of the plasma membrane (9.Leist M. Single B. Castoldi A.F. Kuhnle S. Nicotera P. J. Exp. Med. 1997; 185: 1481-1486Crossref PubMed Scopus (1637) Google Scholar, 10.Richter C. Schweizer M. Cossarizza A. Franceschi C. FEBS Lett. 1996; 378: 107-110Crossref PubMed Scopus (446) Google Scholar). tumor necrosis factor-α transforming growth factor-β granulocyte macrophage-colony stimulating factor ribonuclease protection assay glyceraldehyde-3-phosphate dehydrogenase tumor necrosis factor-α transforming growth factor-β granulocyte macrophage-colony stimulating factor ribonuclease protection assay glyceraldehyde-3-phosphate dehydrogenase The growth inhibitory effect of TNF on hematopoietic progenitor cells has been widely observed in various systems (3.Zucali J.R. Elfebein J. Barth K.C. Dinarello C.A. J. Clin. Invest. 1987; 80: 772-777Crossref PubMed Scopus (49) Google Scholar, 4.Jacobsen S.E.W. Ruscetti F.W. Dubois C.M. Keller J.R. J. Exp. Med. 1992; 175: 1759-1772Crossref PubMed Scopus (86) Google Scholar, 5.Rusten L.S. Smeland E.B. Jacobsen F.W. Lien E. Lesslauer W. Loetsche H. Dubois C.M. Jacobsen S.E.W. J. Clin. Invest. 1994; 94: 165-172Crossref PubMed Scopus (62) Google Scholar, 6.Zhang Y. Harada A. Bluethmann H. Wang J.B. Nakao S. Mukaida N. Matsushima K. Blood. 1995; 86: 2930-2937Crossref PubMed Google Scholar). Although the growth inhibition has been reported to be mediated by TNF p55 receptor (11.Tartaglia L.A. Ayres T.M. Wong G.H.W. Goeddel D.V. Cell. 1972; 74: 845-849Abstract Full Text PDF Scopus (1163) Google Scholar), the cytoplasmic and nuclear events in response to TNF is not clear at all. There is no evidence suggesting that the growth inhibition of these hematopoietic cells is a result of TNF-induced apoptosis or necrosis. Cytoplasmic protease systems have recently been identified as important regulators of intracellular activities including programmed cell death, protein kinase activities, and cell-cycle progression (12.Croall D.E. DeMartino G.N. Physiol. Rev. 1991; 71: 813-847Crossref PubMed Scopus (779) Google Scholar, 13.Pahl H. Baeuerle P.A. Curr. Opin. Cell Biol. 1996; 8: 340-347Crossref PubMed Scopus (140) Google Scholar, 14.Ciechanover A. Cell. 1994; 79: 13-21Abstract Full Text PDF PubMed Scopus (1590) Google Scholar). A typical example is the degradation of IκBα during TNF-induced apoptosis. Degradation of IκBα leads to activation of transcription factor NF-κB, which is required for TNF-regulated gene expression and downstream activities (15.Ghosh S. Baltimore D. Nature. 1990; 344: 678-682Crossref PubMed Scopus (904) Google Scholar, 16.Brown K. Park S. Kanno T. Franzoso G. Siebenlist U. Proc. Natl. Acad. Sci. U. S. A. 1993; 90: 2532-2536Crossref PubMed Scopus (575) Google Scholar, 17.Beg A.A. Finco T.S. Nantermet P.V. Baldwin Jr., A.S. Mol. Cell. Biol. 1993; 13: 3301-3310Crossref PubMed Google Scholar). These previous studies prompted us to investigate the mechanism by which TNF suppresses proliferation of myeloid leukemia cells. We used two myeloid leukemia cell lines, TF-1 and MV4–11, as model systems in our studies, since they are very sensitive to TNF treatment. TF-1 is a growth factor-dependent human erythroid cell line that originally was isolated from the bone marrow cells of a patient with erythroleukemia. Since the TF-1 cell line expressed various cytokines and cytokine receptors and is sensitive to TNF inhibitory effect, this cell line has been a well established model for studying apoptosis, differentiation, and cytokine-regulated gene expression. MV4–11 is a growth factor-independent myeloid leukemia cell line isolated from a child with acute myeloid leukemia. Our previous studies demonstrated that this cell line is very sensitive to TGFβ-induced G1arrest (18.Hu X. Cress D.W. Zhong Q. Zuckerman K.S. Biochem. Biophys. Res. Commun. 2000; 276: 930-939Crossref PubMed Scopus (12) Google Scholar). We have now found that this cell line is also sensitive to TNF-induced cell cycle arrest. Our data showed that TNF caused a significant reduction of D-type cyclins and induced G1arrest in both TF-1 and MV4–11 cells. The down-regulation of the D-type cyclins is a result of proteasome-dependent degradation. Antibodies used and their sources were as follows: antibodies to IκBα, cyclin-dependent kinase 2 (cdk2), cdk4, cdk6, cyclin A, cyclin E, cyclin D1, cyclin D2, cyclin D3, p27, and actin (Santa Cruz Biotechnology, Santa Cruz, CA); pRb, phosphorylated pRb, and luciferase (Promega, Madison, WI). Recombinant human granulocyte macrophage-colony stimulating factor (GM-CSF) and TNF were purchased from Immunex (Seattle, WA) and R&D Systems (Minneapolis, MN), respectively. D-type cyclin probe template and ribonuclease protection assay (RPA) kit were purchased from BD PharMingen (San Diego, CA). Protein G-agarose was obtained from Amersham Biosciences (Piscataway, NJ). [γ-32P]ATP and [35S]methionine were supplied from ICN (Costa Mesa, CA) and PerkinElmer (Boston, MA), respectively. Propidium iodide and RNase A were purchased from Sigma. Culture media, fetal bovine serum, and TRIzol reagent were purchased from Invitrogen (Grand Island, NY). Proteasome and calpain inhibitors were obtained from Calbiochem Corp. (San Diego, CA) and BioMol Research Laboratories (Plymouth Meeting, PA), respectively. Caspase inhibitor (zVAD-FMK) was purchased from Biochem (La Jolla, CA). Ubiquitin Protein Conjugating and 26 S Protein Degradation Kits were obtained fromCalbiochem Corp. TNT Transcription/Translation kits were purchased from Promega (Madison, WI). pRc/CMV/cyclin D3 was a generous gift of Dr. Armando Felsani (CNR, Istituto Tecnologie Biomediche, Roma, Italy). Human TF-1 and MV4–11 cell lines were purchased from the American Type Culture Collection (ATCC, Manassas, VA). These cell lines were routinely maintained in suspension culture in RPMI 1640 (for TF-1) and Iscove's modified Dulbecco's medium (for MV4–11) supplemented with 10% heat-inactivated fetal bovine serum in the absence (for MV4–11) or presence (for TF-1) of 5 ng/ml GM-CSF. The cultures were incubated at 37 °C under 5% CO2 in a humidified atmosphere. Before treatment with TNF, exponentially growing cells were collected by centrifugation and resuspended in RPMI 1640 with 1 ng/ml GM-CSF (For TF-1) or Iscove's modified Dulbecco's medium supplemented with 10% fetal bovine serum at a density of 5 × 105 cells/ml. In some experiments, exponentially growing cells were pretreated with inhibitors of caspase 3, proteasome, or calpain for 30 min at 37 °C, after which TNF was added and the incubation was continued for the times required. Cells in log-phase growth were harvested by centrifugation, washed once with phosphate-buffered saline, and re-cultured in RPMI 1640 supplemented with 10% fetal bovine serum for the times required in a humidified atmosphere containing 5% CO2 at 37 °C. The cells were then harvested, washed once with phosphate-buffered saline, and resuspended in 1 ml of phosphate-buffered saline at a concentration of 2 × 106 cells/ml. Subsequently, 2 ml of methanol were added and the cells were incubated for 30 min on ice. The cells were then collected by centrifugation and resuspended in 500 μl of propidium iodide (0.1 mg/ml) and 100 μl of RNase A (2 mg/ml) for 30 min in the dark at room temperature, after which DNA content was determined using a flow cytometer (BD PharMingen). Cells were collected by centrifugation and washed once with phosphate-buffered saline. Whole lysates and nuclear extracts were prepared as described previously (19.Hu X. Janssen W.E. Moscinski L.C. Bryington M. Dangsup A. Rezai-Zadeh N. Babbin B.A. Zuckerman K.S. Cancer Res. 2001; 61: 6290-6296PubMed Google Scholar). For immunoprecipitation, lysates containing 500 μg of total proteins were incubated with an appropriate antibody (1–2 μg/ml) for 2 h at room temperature or overnight with agitation at 4 °C. About 30 μl of protein A- or protein G-agarose beads were added to the lysates and the incubation continued for another 2 h at the same conditions. Immune complexes were then collected by centrifugation, washed three times with lysis buffer (18.Hu X. Cress D.W. Zhong Q. Zuckerman K.S. Biochem. Biophys. Res. Commun. 2000; 276: 930-939Crossref PubMed Scopus (12) Google Scholar), and resuspended in 2 × SDS sample buffer (125 mmTris-HCl, pH 6.8, 4% SDS, 20% glycerol, 100 mmdithiothreitol, 0.2% bromphenol blue). Lysates in sample buffer were analyzed for the expression of proteins by Western blotting (18.Hu X. Cress D.W. Zhong Q. Zuckerman K.S. Biochem. Biophys. Res. Commun. 2000; 276: 930-939Crossref PubMed Scopus (12) Google Scholar) and detected by a chemiluminescence (New England BioLabs, Beverly, MA). For direct Western blotting, lysates containing 30–50 μg of total proteins were loaded on SDS-PAGE gels followed by Western blotting procedure (18.Hu X. Cress D.W. Zhong Q. Zuckerman K.S. Biochem. Biophys. Res. Commun. 2000; 276: 930-939Crossref PubMed Scopus (12) Google Scholar). Preclarified lysates (200 μg of total protein) extracted from cells treated with or without TNF were immunoprecipitated for 2 h at 4 °C with an antibody against cyclin or cdk followed by addition of protein G-agarose beads for 2 h. The lysates were collected by centrifugation and washed. After three washes in lysis buffer (20 mm Tris, 150 mm NaCl, 1 mm EDTA, 1 mm EGTA, 1% Triton, 2.5 mm sodium pyrophosphate, 1 mmβ-glycerophosphate, 1 mm phenylmethylsulfonyl fluoride, 1 mm sodium orthovanadate, 1 μg/ml leupeptin) and two washes in kinase buffer (50 mm Hepes, pH 7.5, 10 mm MgCl2, 10 mm dithiothreitol), the kinase reaction was carried out in a total volume of 10 μl, which included 5 μl of 2 × kinase buffer containing 10 μCi of [γ-32P]ATP and 2 μg of GST-Rb at 30 °C for 30 min. The reaction was stopped by adding 10 μl of 2 × sample buffer and boiling for 4 min before separation by SDS-PAGE. The gel was then dried and exposed to film (Kodak XAR-5). Cells were treated with or without TNF for different times. One hour prior to harvesting, culture medium was replaced with methionine-free medium supplemented with 10% fetal bovine serum and 300 μCi/ml [35S]methionine. Cells were then collected and cell lysates were prepared in lysis buffer. An equal amount of protein from each sample were immunoprecipitated with an antibody against cyclins D2 or D3 followed by addition of protein G-agarose. Subsequently, the immunoprecipitates were resolved by SDS-PAGE, and visualized by autoradiography. For pulse-chase experiments, cells treated with or without TNF for 48 h were collected and resuspended in normal culture medium containing [35S]methionine for 1 h, at 37 °C, after which the labeling medium were removed and cells were incubated in the presence of an excess of nonradioactive methionine for 1–4 h. Cells were then collected, cell lysates were prepared, and immunoprecipitated with an antibody against cyclins D2 or D3 following the procedure described above. In vitroprotease activity assays were performed as described previously (20.Rock K.L. Gramm C. Rothstein L. Clark K. Stein R. Dick L. Hwang D. Goldberg A.L. Cell. 1994; 78: 761-771Abstract Full Text PDF PubMed Scopus (2185) Google Scholar), with slight modification. Preclarified lysates (200 μg of total protein) extracted from cells treated with or without TNF were incubated with peptide-AMC substrate (Calbiochem, San Diego, CA)-containing reaction buffer (20 mm Tris-HCl, 1 mm ATP, 2 mm MgCl2) in the presence or absence of the indicated protease inhibitor (30 min, 30 °C). Fluorescent product, AMC, released from the reaction, were quantitated by measuring fluorescence emission intensity at 440 nm. Transcription and translation of pRC/CMV/cyclin D3 using TNT reticulocyte lysate (Promega) were performed following the manufacturer's instruction without 35S labeling. Translation products were incubated in 1 × ubiquitin reaction buffer, which contained ATP, E1, E2, and E3, at 37 °C for 2 h, after which the reaction product were transfer to quenching buffer (10% trichloroacetic acid, 200 μl of 5% bovine serum albumin) followed by addition of 26 S proteasome fractions (Calbiochem, San Diego, CA). The degradation reaction was performed at 37 °C for 1–1.5 h following the manufacturer's instruction. After reaction, aliquots of reaction mixture were loaded to SDS-PAGE and the expression of cyclin D3 was analyzed by Western blot with a specific antibody against cyclin D3. Total RNA was isolated from cells treated with or without TNF using TRIzol reagent following the manufacturer's protocol. RNA concentrations were determined using a spectrophotometer. RPA was then performed using the RPA kit following the manufacturer's instructions. Briefly, a labeled RNA probe was synthesized by T1 RNA polymerase in the presence of RPA template and [α-32P]UTP. The RPA template contains the cDNAs encoding cylin B, cyclin C, cyclin D1, cyclin D2, cyclin D3, L32, and GAPDH, respectively. The labeled probe was then mixed with the sample RNA at 56 °C for 14 h followed by at 37 °C for 15 min. After hybridization, RNase A was added and incubated at 30 °C for 45 min. After RNase digestion was completed, the samples (target RNAs) were separated on a polyacrylamide gel, and protected mRNAs were visualized by autoradiography. Quantities of proteins detected by invitro kinase assay, Western blot, and immunoprecipitation were quantitated by image reading, using ImageQuant (Molecular Dynamics, Sunnyvale, CA). The numbers produced were proportional to the degree of protein expression. Percent decreases or increases in protein levels were then calculated. Cell cycle data were expressed as the mean from two to four separate experiments. The statistical significance of differences between group means or protein quantities was determined using the Student's t test. When studying the apoptotic effect of TNF-α on TF-1 human erythroid leukemia cells, we observed that the cells also showed cell cycle arrest features. Cell cycle analysis by flow cytometry showed that TNF induced a G1 arrest. In normal culture conditions, 43% of TF-1 cells in G1 and 44% of the cells in S phases. TNF, at a concentration of 30 ng/ml for 24 h, increased the proportion of G1 cells to 67% and decreased the proportion of S cells to 14%. Longer incubation time (48 h) of cells with TNF slightly increased G1 population and decreased S population (Fig. 1A). TNF-induced G1arrest is not limited to this particular cell line, since the same concentration of TNF also brought about significant G1arrest in MV4–11 cells. Approximately, 55% of cells were distributed in G1 and 41% of cells in S in control MV4–11 cells. Treatment of cells with TNF caused a marked increase of G1cells to 76% and a decrease of S cells to 11% by 24 h. Since the phosphorylation status of pRb (the retinoblastoma gene product) and the expression of “cdk inhibitor” p27 have been linked to cell cycle status, we next investigated whether TNF-induced G1 arrest accompanied with an alteration in pRb phosphorylation or p27 expression. In exponentially growing phase, TF-1 and MV4–11 cells (0 time) expressed both underphosphorylated (bottom band) and phosphorylated pRb (top band) proteins at a molecular size of ∼110 kDa. By 24 and 48 h after addition of TNF to the cells, the phosphorylated pRb (slowest moving form, top band) was decreased by 70–80% in both TF-1 and MV4–11 cells (Fig. 1 B). To determine whether the decrease in pRb is related to phosphorylation of pRb, a specific antibody against phosphorylated pRb (Ser-795) was used for further blotting experiments. As shown in Fig. 1 B, phosphorylated pRb is expressed in exponentially growing TF-1 and MV4–11 cells (0 h) as a single band in SDS-PAGE and was dramatically decreased within 24–48 h after initiating TNF treatment. TNF-induced dephosphorylation of pRb is similar to the effect of TGFβ on pRb in these cells. TNF also caused a marked accumulation of p27. In the absence of TNF, both TF-1 and MV4–11 cells expressed relatively small amounts of p27, addition of TNF led to a marked increase of p27, with ∼20-fold (in MV4–11) and 35-fold (in TF-1) increase of p27 being observed by 48 h, as measured by image reading, using ImageQuant (Fig. 1 B). Since synthesis of D-type cyclins and phosphorylation of pRb are at approximately the same time in G1 and since D-type cyclins play a critical role in G1 progression and G1-S transition (21.Matsushime H. Roussel M.F. Ashmun R.A. Sherr C.J. Cell. 1991; 65: 701-713Abstract Full Text PDF PubMed Scopus (988) Google Scholar, 22.Xiong Y. Connolly T. Futcher B. Beach D. Cell. 1991; 65: 691-699Abstract Full Text PDF PubMed Scopus (587) Google Scholar), we asked whether TNF affects the abundance of the D-type cyclins and their catalytic subunits. Thus, the expression of D-type cyclins, cdk2, cdk4, and cdk6 was examined by Western blotting before and after TNF treatment. Proliferating TF-1 cells not exposed to TNF expressed cyclin D2, cyclin D3, cdk2, cdk4, and cdk6 at ∼33–35 kDa, and addition of TNF caused a considerable decrease of cyclins D2 and D3, with 65 and 70% decrease being detected by 48 h, respectively. Compared with the expression of cyclins D2 and D3, TF-1 cells expressed relatively low levels of cyclin D1 and addition of TNF for 24 or 48 h suppressed cyclin D1 to a lesser extent (42%) than cyclins D2 and D3 (Fig. 2 A). Incubation with TNF for less than 12 h had no significant effect on the expression of these cyclins. We confirmed that there was equivalent loading of total proteins, because cells treated with or without TNF expressed the same levels of actin (negative control). In addition, there were no detectable alterations in the expression of cdk2, cdk4, or cdk6 at any time point up to 48 h after initiating TNF treatment. TNF similarly suppressed the expression of cyclins D2 and D3 in MV4–11 cells. However, cyclin D1 was barely detected in this cell line (data not shown). The effect of TNF on the expression of D-type cyclins is dose- and time-dependent with a maximal inhibition of cyclin D3 being detected by 48 h and at a concentration range of 20–40 ng/ml TNF (data not shown). Next, we investigated D-type cyclin-dependent kinase activities, using in vitro kinase assays. Since the expression of cyclin D1 was very low in these two cell lines, we focused on the cyclin D2 and cyclin D3. TF-1 cells grown in the absence or presence of TNF (30 ng/ml) for 48 h were collected and lysed. Cell lysates were then immunoprecipitated with antibodies against cyclins D2, D3, or IgG. The immunoprecipitates were then incubated with GST-Rb fusion protein in the presence of [γ-32P] ATP as described under “Experimental Procedures.” The expression of phosphorylated GST-Rb was detected by autoradiography. High levels of cyclins D2- and D3-dependent kinase activities were observed in TF-1 cells in the absence of TNF. In contrast, cells treated with TNF for 48 h showed very low cyclin D2- and D3-dependent kinase activities, based on the expression of phosphorylated GST-Rb, with decreases of 55 and 87% of being observed, respectively. As negative controls, IgG immunoprecipitates either from proliferating TF-1 cells or from the cells treated with TNF lacked kinase activity (Fig. 2 B). Since D-type cyclins are mainly associated with cdk4, and the cyclin-cdk complexes play a critical role in G1 progression, we also examined cdk4 kinase activity. As expected, exposure to TNF for 48 h caused a dramatic decrease of cdk4 kinase activity with ∼90% decrease being detected. Cyclin-cdk4 complexes are assumed to modify pRb, thereby promoting cell cycle progression toward DNA replication. By using a combination of immunoprecipitation and Western blot, we detected that association of D-type cyclins with pRb was significantly decreased in the cells treated with TNF for 48 h due to a decrease of total D-type cyclins (data not shown). Hypodiploid DNA (see sub-G1population) was observed in both TF-1 and MV4–11 cells treated with TNF (Fig. 1 A), suggesting that TNF caused apoptotic cell death in these cells, which is consistent with previous observations (23.Hu X. Tang M. Fisher A.B. Olashaw N. Zuckerman K.S. J. Immunol. 1999; 163: 3106-3115PubMed Google Scholar). One might expect that the G1 arrest could result from apoptosis. To study the association between G1 arrest and apoptosis, we measured caspase-3 activation and D-type cyclin expression before and after TNF treatment in the absence and presence of a caspase-3 inhibitor. It has been reported that caspase-3 is a key protease that becomes activated during TNF-induced apoptosis. Activated caspase-3 consists of multiple subunits, including 19 kDa, 17 kDa, and possible other smaller subunits, depending on the activity of caspase 3 and the cell type. TF-1 cells in the absence of TNF expressed 32-kDa proenzyme and barely activated caspase 3. However, a 24-h incubation with TNF caused a significant expression of activated caspase 3 (Fig. 3 A), evidenced by appearance of 19-, 17-, and 14-kDa proteins, detected by using both anti-caspase (top panel) and anti-specific activated caspase 3 (thesecond panel from top) antibodies. The specificity of caspase 3 activation was confirmed by using caspase inhibitor, zVAD-FMK, since the inhibitor at a concentration of 100 μm completely inhibited TNF-induced activation of caspase 3. In contrast, the inhibitor was not able to block TNF-induced down-regulation of the D-type cyclins and G1 arrest at any dose up to 200 μm. However, zVAD-FMK partially reduced the TNF-induced sub-G1 population (Fig. 3, A andB). To further ensure that the inhibition of D-type cyclins was not secondary to TNF-induced apoptosis, we analyzed patterns of cyclin D3 inhibition and cell death. The inhibition of cyclin D3 was dose-dependent with a maximal inhibition of 85% being detected at a concentration of 30 ng/ml TNF, above which the level of cyclin D3 was not further decreased. In contrast, the cell death caused by TNF increased lineally with increasing TNF concentration, with maximal cell death being observed at a concentration of 50 ng/ml TNF. In addition, TNF at a concentration of 10 ng/ml induced activation of caspase 3 but not inhibition of D-type cyclins (Fig. 3 C). These results demonstrated that TNFα-induced G1 arrest is caspase 3 pathway-independent. The TNF-induced down-regulation of D-type cyclins could be potentially regulated at mRNA or proteins levels. To test the first possibility, RPA were performed. As illustrated in Fig. 4 A, cells expressed cyclin D3, cyclin D2, and little cyclin D1 mRNAs. Addition of TNF (30 ng/ml) had no effect on the levels of mRNA encoding cyclins D1 and D2, but caused modest reduction in the levels of mRNA for cyclin D3 with a decrease of 22% being detected by 48 h measured using ImageQuant software. Control and TNF-treated cells showed the same levels of mRNAs for housekeeping genes, L32 and GAPDH, which were used as controls and references for normalizing samples. Unexpected, TNFα dramatically down-regulated the expression of mRNA for cyclin B, which is involved primarily in regulation of the G2-M transition of the cell cycles. Thus, the specific inhibitory effects of TNF on G1 regulatory molecules appear to be mainly at post-transcriptional levels. Two possibilities may account for the down-regulation of D-type cyclins at post-transcriptional levels: 1) TNF induces a decrease of biosynthesis rate of D-type cyclins; or 2) TNF causes a degradation of D-type cyclins. To clarify this question, MV4–11 cells were treated with or without TNF for 24 and 48 h, after which cells were labeled with [35S]methionine for 1 h and the expression of cyclins D2 and D3 were detected by autoradiography. As showed in Fig. 4 B, control cells (TNF−) expressed labeled cyclins D2 and D3, representing new synthesis of these cyclins. Addition of TNF for 24 h caused ∼50% decreases in the quantities of cyclins D2 and D3. However, further increase of incubation time (48 h) with TNF did not further down-regulate the levels of cyclins D2 and D3, suggesting that TNF induced down-regulation of D-type cyclins is most likely not related to biosynthesis rate. However, if cells were chased for different times with normal culture medium containing unlabeled methionine after they released from medium containing [35S]methionine, we observed a chase time-dependent reduction in the amounts of labeled cyclins D2 and D3 in the cells treated with TNF, with maximal reductions of 65 to 70% being detected by 4 h (Fig. 4,B and C). In contrast, the expression of cyclin E was not affected by TNF treatment. Thus, TNF-induced down-regulation of D-type cyclins appears to be a result of degradation. This was confirmed by the approach of using degradation inhibitors. Since degradation of IκBα by TNF has been well established, we wondered if degradation of IκBα was linked to D-type cyclin expression. To clarify this question, the expression of IκBα and D-type cyclins in the absence and presence of TNF and several protein degradation inhibitors was examined by Western blotting. ALLN is a calpain-dependent inhibitor, lactacystin is both a proteasome and calpain-dependent inhibitor, and zVAD-FMA is a

TNF-α Upregulates PTEN Via NF-κB Signaling Pathways in Human Leukemic Cells

TNF-α Up-Regulates Protein Tyrosine Phosphatase 1B Via NF-kB in HepG2 Cells

TNF-alpha-induced Growth Suppression of CD34+ Myeloid Leukemic Cell Lines Signals Through TNF Receptor Type I and is Associated with NF-kappa B Activation.

Tumor Necrosis Factor-α Contributes to Microenvironmental up- Regulation of NF-κB Activity in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Implication for a Novel Therapeutic Target.

TNF-α Affects Human Cortical Neural Progenitor Cell Differentiation Through the Autocrine Secretion of Leukemia Inhibitory Factor.

Myeloid PTEN Promotes Chemotherapy-Induced NLRP3-inflammasome Activation and Antitumour Immunity

Tumor Necrosis Factor Α Promotes HEp-2 Cell Proliferation Via Toll-Like Receptor 4 and NF-κB Signaling Pathways.

PTENα functions as an immune suppressor and promotes immune resistance in PTEN-mutant cancer

TNF-α Differentially Regulates Cell Cycle Genes in Promyelocytic and Granulocytic HL-60/S4 Cells

NR4A1-induced Increase in the Sensitivity of a Human Gastric Cancer Line to TNFα-mediated Apoptosis is Associated with the Inhibition of JNK/Parkin-dependent Mitophagy.

Transmembrane Tnf-Alpha Mediates "forward" and "reverse" Signaling, Inducing Cell Death or Survival Via the Nf-Kappa B Pathway in Raji Burkitt Lymphoma Cells

Expression of TNF-α leader sequence renders MCF-7 tumor cells resistant to the cytotoxicity of soluble TNF-α

Modulation of the protein expression of TLR2 by TNF-α in primary rat renal proximal tubule cells

Transmembrane TNF-A Promotes Suppressive Activities of Myeloid-Derived Suppressor Cells via TNFR2

Ubiquitin/Proteasome-dependent Degradation of D-type Cyclins is Linked to Tumor Necrosis Factor-induced Cell Cycle Arrest

Inhibition of RNA Polymerase III Augments the Anti-Cancer Properties of TNFα

Selective regulation of tumor necrosis factor–induced Erk signaling by Src family kinases and the T cell protein tyrosine phosphatase

Post-transcriptional and post-translational regulation of PTEN by transforming growth factor-β1

Application Of Transcriptional And Posttranscriptional Reporter Constructs To The Analysis Of Tumor-Necrosis-Factor Gene-Regulation

Prion protein is required for tumor necrosis factor α (TNFα)-triggered nuclear factor κB (NF-κB) signaling and cytokine production

Phosphorylation of Heat Shock Protein 27 Antagonizes TNF-α Induced HeLa Cell Apoptosis Via Regulating TAK1 Ubiquitination and Activation of P38 and ERK Signaling.